ZNF239 Knockout cell line (SU-DHL-1)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZNF239 (zinc finger protein 239) encodes a MOK2-family DNA- and RNA-binding protein that is primarily associated with nuclear ribonucleoprotein components, including nucleolar and extranucleolar structures. Through its association with nuclear RNP complexes, ZNF239 may participate in the regulation or organization of RNA-associated nuclear processes.

The SU-DHL-1 cell line was established in 1973 from the pleural effusion of a 10-year-old male patient. Originally diagnosed as diffuse histiocytic lymphoma, the tumor was subsequently reclassified as diffuse large cell lymphoma and later as malignant histiocytosis. According to the REAL/WHO classification, the cell line represents anaplastic large cell lymphoma (ALCL) and carries the t(2;5)(p23;q35) translocation resulting in an NPM1-ALK (NPM-ALK) fusion gene. SU-DHL-1 is used as a model for studying ALCL biology and ALK-associated oncogenic signaling.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.